BACKGROUND: Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) provides greater protection from placental malaria than sulfadoxine-pyrimethamine (SP). Some studies suggest placental malaria alters risk of malaria infection in infants, but few have quantified the effect of IPTp on infant susceptibility to malaria. METHODS: Infants born to women enrolled in a randomized clinical trial comparing IPTp-SP and IPTp-DP in Malawi were followed from birth to 24 months to assess effect of IPTp and placental malaria on time to first malaria episode and Plasmodium falciparum incidence. RESULTS: In total, 192 infants born to mothers randomized to IPTp-SP and 195 randomized to IPTp-DP were enrolled. Infants in IPTp exposure groups did not differ significantly regarding incidence of clinical malaria (incidence rate ratio [IRR], 1.03; 95% confidence interval [CI], .58-1.86) or incidence of infection (IRR, 1.18; 95% CI, .92-1.55). Placental malaria exposure was not associated with incidence of clinical malaria (IRR, 1.03; 95% CI, .66-1.59) or infection (IRR, 1.15; 95% CI, .88-1.50). Infant sex, season of birth, and maternal gravidity did not confound results. CONCLUSIONS: We did not find evidence that IPTp regimen or placental malaria exposure influenced risk of malaria during infancy in this population. Clinical Trials Registration. NCT03009526.
BACKGROUND: Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) provides greater protection from placental malaria than sulfadoxine-pyrimethamine (SP). Some studies suggest placental malaria alters risk of malaria infection in infants, but few have quantified the effect of IPTp on infant susceptibility to malaria. METHODS: Infants born to women enrolled in a randomized clinical trial comparing IPTp-SP and IPTp-DP in Malawi were followed from birth to 24 months to assess effect of IPTp and placental malaria on time to first malaria episode and Plasmodium falciparum incidence. RESULTS: In total, 192 infants born to mothers randomized to IPTp-SP and 195 randomized to IPTp-DP were enrolled. Infants in IPTp exposure groups did not differ significantly regarding incidence of clinical malaria (incidence rate ratio [IRR], 1.03; 95% confidence interval [CI], .58-1.86) or incidence of infection (IRR, 1.18; 95% CI, .92-1.55). Placental malaria exposure was not associated with incidence of clinical malaria (IRR, 1.03; 95% CI, .66-1.59) or infection (IRR, 1.15; 95% CI, .88-1.50). Infant sex, season of birth, and maternal gravidity did not confound results. CONCLUSIONS: We did not find evidence that IPTp regimen or placental malaria exposure influenced risk of malaria during infancy in this population. Clinical Trials Registration. NCT03009526.
Authors: Meghna Desai; Feiko O ter Kuile; François Nosten; Rose McGready; Kwame Asamoa; Bernard Brabin; Robert D Newman Journal: Lancet Infect Dis Date: 2007-02 Impact factor: 25.071
Authors: Christopher L King; Indu Malhotra; Alex Wamachi; John Kioko; Peter Mungai; Sherif Abdel Wahab; Davy Koech; Peter Zimmerman; John Ouma; James W Kazura Journal: J Immunol Date: 2002-01-01 Impact factor: 5.422
Authors: Julie Gutman; Dyson Mwandama; Ryan E Wiegand; Doreen Ali; Don P Mathanga; Jacek Skarbinski Journal: J Infect Dis Date: 2013-06-24 Impact factor: 5.226
Authors: Indu Malhotra; Peter Mungai; Eric Muchiri; John Ouma; Shobhona Sharma; James W Kazura; Christopher L King Journal: Infect Immun Date: 2005-06 Impact factor: 3.441
Authors: Abel Kakuru; Prasanna Jagannathan; Mary K Muhindo; Paul Natureeba; Patricia Awori; Miriam Nakalembe; Bishop Opira; Peter Olwoch; John Ategeka; Patience Nayebare; Tamara D Clark; Margaret E Feeney; Edwin D Charlebois; Gabrielle Rizzuto; Atis Muehlenbachs; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: N Engl J Med Date: 2016-03-10 Impact factor: 91.245
Authors: Matthew Adams; Sudhaunshu N Joshi; Gillian Mbambo; Amy Z Mu; Shay M Roemmich; Biraj Shrestha; Kathy A Strauss; Nicole Eddington Johnson; Khine Zaw Oo; Tin Maung Hlaing; Zay Yar Han; Kay Thwe Han; Si Thura; Adam K Richards; Fang Huang; Myaing M Nyunt; Christopher V Plowe Journal: Malar J Date: 2015-12-23 Impact factor: 2.979
Authors: Timothy Awine; Mark M Belko; Abraham R Oduro; Sunny Oyakhirome; Harry Tagbor; Daniel Chandramohan; Paul Milligan; Matthew Cairns; Brian Greenwood; John E Williams Journal: Malar J Date: 2016-01-28 Impact factor: 2.979
Authors: Prasanna Jagannathan; Abel Kakuru; Jaffer Okiring; Mary K Muhindo; Paul Natureeba; Miriam Nakalembe; Bishop Opira; Peter Olwoch; Felistas Nankya; Isaac Ssewanyana; Kevin Tetteh; Chris Drakeley; James Beeson; Linda Reiling; Tamara D Clark; Isabel Rodriguez-Barraquer; Bryan Greenhouse; Erika Wallender; Francesca Aweeka; Mary Prahl; Edwin D Charlebois; Margaret E Feeney; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: PLoS Med Date: 2018-07-17 Impact factor: 11.069
Authors: Abel Kakuru; Prasanna Jagannathan; Richard Kajubi; Teddy Ochieng; Harriet Ochokoru; Miriam Nakalembe; Tamara D Clark; Theodore Ruel; Sarah G Staedke; Daniel Chandramohan; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: BMC Med Date: 2020-08-10 Impact factor: 8.775